Condition: RSV Immunisation · Sponsor: Karin Karin Loré
Respiratory syncytial virus (RSV) is a common cause of respiratory tract infections leading to hospitalizations in infants and in elderly. Arexvy is an approved vaccine for the prevention of RSV infection, however, data on its efficacy in individuals aged 80 years and older remain limited. This study aims to evaluate potential differences in immune responses to Arexvy vaccination between adults aged ≥80 years and those aged 60-65 years.
This description comes directly from the study's public registry record.
Karin Loré, Professor · +46852480000 · karin.lore@ki.se
Florian Gegenfurtner, MSc · +46852480000 · florian.gegenfurtner@ki.se
Always discuss trial participation with your own doctor first.
| Familjeläkarna SÄBO | Saltsjöbaden, Sweden | Recruiting |
| Akademiskt specialistcentrum Studieenheten | Stockholm, Sweden | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07203365